Cabaletta Bio Inc (CABA)

$7.19

+0.44

(+6.52%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $6.85
    $7.21
    $7.19
    downward going graph

    4.73%

    Downside

    Day's Volatility :4.99%

    Upside

    0.28%

    downward going graph
  • $6.71
    $26.35
    $7.19
    downward going graph

    6.68%

    Downside

    52 Weeks Volatility :74.54%

    Upside

    72.71%

    downward going graph

Returns

PeriodCabaletta Bio IncSector (Health Care)Index (Russel 2000)
3 Months
-38.69%
6.5%
0.0%
6 Months
-69.7%
7.1%
0.0%
1 Year
-44.44%
9.8%
0.0%
3 Years
-12.68%
14.2%
-20.2%

Highlights

Market Capitalization
333.6M
Book Value
$4.6
Earnings Per Share (EPS)
-1.71
Wall Street Target Price
33.56
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-31.16%
Return On Equity TTM
-49.06%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-84.3M
Diluted Eps TTM
-1.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.13
EPS Estimate Next Year
-2.22
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Cabaletta Bio Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 366.76%

Current $7.19
Target $33.56

Technicals Summary

Sell

Neutral

Buy

Cabaletta Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cabaletta Bio Inc
Cabaletta Bio Inc
-7.02%
-69.7%
-44.44%
-12.68%
-32.5%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cabaletta Bio Inc
Cabaletta Bio Inc
NA
NA
NA
-2.13
-0.49
-0.31
NA
4.6
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cabaletta Bio Inc
Cabaletta Bio Inc
Buy
$333.6M
-32.5%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Cabaletta Bio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 106.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 199.2%

Institutional Holdings

  • BlackRock Inc

    8.40%

  • State Street Corporation

    7.75%

  • Jennison Associates LLC

    7.09%

  • Fred Alger Management, LLC

    6.44%

  • Adage Capital Partners Gp LLC

    6.29%

  • T. Rowe Price Investment Management,Inc.

    5.12%

Company Information

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un

Organization
Cabaletta Bio Inc
Employees
118
CEO
Dr. Steven A. Nichtberger M.D.
Industry
Health Technology

Discover More

FAQs